Myriad Genetics, Inc. (MYGN) EPS Estimated At $0.24; NORTHSIGHT CAPITAL (NCAP) Shorts Increased By 251.85%

NORTHSIGHT CAPITAL (OTCMKTS:NCAP) had an increase of 251.85% in short interest. NCAP’s SI was 9,500 shares in January as released by FINRA. Its up 251.85% from 2,700 shares previously. With 138,500 avg volume, 0 days are for NORTHSIGHT CAPITAL (OTCMKTS:NCAP)’s short sellers to cover NCAP’s short positions. The stock increased 18.71% or $0.0107 during the last trading session, reaching $0.0679. About shares traded. Northsight Capital, Inc. (OTCMKTS:NCAP) has 0.00% since January 31, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.24 EPS on February, 6.They anticipate $0.02 EPS change or 7.69% from last quarter’s $0.26 EPS. MYGN’s profit would be $16.61M giving it 40.52 P/E if the $0.24 EPS is correct. After having $0.26 EPS previously, Myriad Genetics, Inc.’s analysts see -7.69% EPS growth. The stock increased 1.17% or $0.45 during the last trading session, reaching $38.9. About 641,609 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since January 31, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.

Among 20 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 5 Sell and 11 Hold. Therefore 20% are positive. Myriad Genetics had 53 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Tuesday, September 12. Jefferies has “Hold” rating and $23.0 target. Goldman Sachs upgraded Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Tuesday, December 8. Goldman Sachs has “Neutral” rating and $40 target. The stock has “Neutral” rating by Mizuho on Tuesday, September 15. The rating was maintained by Mizuho on Wednesday, November 4 with “Neutral”. As per Monday, June 12, the company rating was maintained by Jefferies. Barclays Capital maintained Myriad Genetics, Inc. (NASDAQ:MYGN) on Monday, January 22 with “Hold” rating. The rating was upgraded by Wells Fargo on Tuesday, August 25 to “Market Perform”. Deutsche Bank maintained the shares of MYGN in report on Wednesday, November 8 with “Hold” rating. As per Friday, August 18, the company rating was upgraded by Deutsche Bank. As per Friday, September 15, the company rating was maintained by Cowen & Co.

Since September 1, 2017, it had 0 insider buys, and 8 sales for $6.39 million activity. Shares for $1.53 million were sold by MARSH RICHARD M on Thursday, January 18. On Monday, January 22 the insider King Gary A. sold $1.37M. DREISMANN HEINRICH also sold $201,000 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shares. Shares for $248,925 were sold by GILBERT WALTER PHD on Thursday, December 14. 30,000 shares were sold by HENDERSON JOHN T, worth $909,040 on Friday, September 1.

Investors sentiment decreased to 0.86 in 2017 Q3. Its down 0.16, from 1.02 in 2017Q2. It worsened, as 33 investors sold Myriad Genetics, Inc. shares while 72 reduced holdings. 28 funds opened positions while 62 raised stakes. 71.79 million shares or 8.95% less from 78.85 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage Sa stated it has 35,653 shares. Cantab Cap Llp reported 0.25% in Myriad Genetics, Inc. (NASDAQ:MYGN). Creative Planning owns 7,283 shares or 0% of their US portfolio. Macquarie Gp invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Qs Investors Limited Liability Corporation holds 4,283 shares or 0% of its portfolio. Ubs Asset Americas holds 48,339 shares. Mason Street Advsr Ltd invested in 0.02% or 17,333 shares. Moreover, Us National Bank & Trust De has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 2,287 shares. Adams Asset Advisors Ltd Limited Liability Company accumulated 0.19% or 39,301 shares. 137,380 are owned by Rhumbline Advisers. Deutsche Bancorporation Ag has invested 0.01% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Credit Agricole S A reported 144,412 shares or 0.02% of all its holdings. Millrace Asset holds 1.11% or 32,738 shares. Employees Retirement System Of Ohio holds 0.03% in Myriad Genetics, Inc. (NASDAQ:MYGN) or 142,609 shares. State Farm Mutual Automobile Insurance has 404,728 shares for 0.02% of their portfolio.

The post Myriad Genetics, Inc. (MYGN) EPS Estimated At $0.24; NORTHSIGHT CAPITAL (NCAP) Shorts Increased By 251.85% appeared first on Stock Market News | HillCountryTimes | Get it Today.

from
https://www.hillcountrytimes.com/2018/01/31/myriad-genetics-inc-mygn-eps-estimated-at-0-24-northsight-capital-ncap-shorts-increased-by-251-85/